Allogene Q1 net loss $42.6M; ALPHA3 interim shows 58% MRD clearance; cash runway extended to Q1 2029

Allogene Therapeutics, Inc.

2026-Q1 EPS reported -$0.18 vs consensus -$0.19 ▲ beat (+7.3%)

Terminated exclusive license with Overland; retains ~3% equity; no termination payments.
ALPHA3 interim: 58.3% MRD clearance in cema-cel arm vs 16.7% observation; no CRS/ICANS/GvHD.
Q1 net loss $42.6M ($0.18/sh); operating cash expense guidance raised to ~$165M.
Cash $266.9M; April public offering grossed $200.4M; runway into Q1 2029.
ALLO-329 Phase 1 RESOLUTION dosed 9 patients; initial signs of activity; next update Q4 2026.

item 1.01 item 1.02 item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allogene Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2026.

Period: for the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2026 in the press release attached hereto as Exhibit 99.1

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Allogene Therapeutics, Inc. terminated Exclusive License Agreement, dated December 14, 2020, as amended on May 24, 2024 with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. valued at No termination payments were made; upfront payment $40.0 million and non-cash consideration of $79.0 (effective 2026-05-12).

Action: termination
Agreement: license
Counterparty: Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc.
Value: No termination payments were made; upfront payment $40.0 million and non-cash consideration of $79.0
Effective: 2026-05-12

Exact text from the filing

The Termination Agreement provides that the License Agreement is terminated in its entirety, subject to certain customary survival provisions.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Allogene Therapeutics, Inc. entered into Second Amended and Restated Shareholders’ Agreement with Overland Therapeutics Inc. and HH BioPharma Holdings Ltd. valued at Restructuring of Allogene’s equity ownership and governance rights with respect to Overland (effective 2026-05-12).

Action: entry
Counterparty: Overland Therapeutics Inc. and HH BioPharma Holdings Ltd.
Value: Restructuring of Allogene’s equity ownership and governance rights with respect to Overland
Effective: 2026-05-12

Exact text from the filing

The Shareholders Agreement amends and restates the prior shareholders’ agreement and reflects a restructuring of Allogene’s equity ownership and governance rights with respect to Overland.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-034583

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.